Chugai Pharmaceutical Future Growth
Future criteria checks 2/6
Chugai Pharmaceutical is forecast to grow earnings and revenue by 6.2% and 4.4% per annum respectively. EPS is expected to grow by 6.2% per annum. Return on equity is forecast to be 17% in 3 years.
Key information
6.2%
Earnings growth rate
6.2%
EPS growth rate
| Pharmaceuticals earnings growth | 11.7% |
| Revenue growth rate | 4.4% |
| Future return on equity | 17.0% |
| Analyst coverage | Good |
| Last updated | 21 Nov 2024 |
Recent future growth updates
Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29
Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 30Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Apr 26Recent updates
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 30Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 15Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?
Oct 12Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Sep 24Results: Chugai Pharmaceutical Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 30Chugai Pharmaceutical (TSE:4519) Is Due To Pay A Dividend Of ¥41.00
Jul 27Estimating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Jul 15Chugai Pharmaceutical (TSE:4519) Is Increasing Its Dividend To ¥41.00
Jun 19Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Trailing The Market But Its Shares Aren't
Jun 17Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year
May 04We Think That There Are Some Issues For Chugai Pharmaceutical (TSE:4519) Beyond Its Promising Earnings
May 01Chugai Pharmaceutical Co., Ltd. (TSE:4519) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Apr 26Chugai Pharmaceutical Co., Ltd. (TSE:4519) Investors Are Less Pessimistic Than Expected
Mar 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,224,223 | 425,265 | 375,458 | 428,567 | 13 |
| 12/31/2025 | 1,160,101 | 389,690 | 351,336 | 414,183 | 15 |
| 12/31/2024 | 1,135,976 | 377,369 | 332,760 | 371,800 | 15 |
| 9/30/2024 | 1,142,350 | 386,964 | 349,434 | 419,416 | N/A |
| 6/30/2024 | 1,084,570 | 355,041 | 265,465 | 327,068 | N/A |
| 3/31/2024 | 1,036,076 | 326,373 | 323,991 | 383,090 | N/A |
| 12/31/2023 | 1,111,367 | 325,472 | 350,827 | 409,925 | N/A |
| 9/30/2023 | 1,276,051 | 336,745 | 205,825 | 258,712 | N/A |
| 6/30/2023 | 1,243,437 | 326,969 | 200,169 | 252,605 | N/A |
| 3/31/2023 | 1,211,632 | 316,154 | 252,376 | 299,319 | N/A |
| 12/31/2022 | 1,259,946 | 374,429 | 172,873 | 244,112 | N/A |
| 9/30/2022 | 1,143,716 | 370,791 | 298,989 | 366,072 | N/A |
| 6/30/2022 | 1,205,696 | 389,011 | 339,236 | 422,551 | N/A |
| 3/31/2022 | 1,191,496 | 387,359 | 227,919 | 305,626 | N/A |
| 12/31/2021 | 999,759 | 302,995 | 206,760 | 279,626 | N/A |
| 9/30/2021 | 887,919 | 256,462 | 180,866 | 256,890 | N/A |
| 6/30/2021 | 809,055 | 230,577 | 194,361 | 252,664 | N/A |
| 3/31/2021 | 776,339 | 210,611 | 165,601 | 246,567 | N/A |
| 12/31/2020 | 786,946 | 214,733 | 143,646 | 205,035 | N/A |
| 9/30/2020 | 753,853 | 202,590 | 127,482 | 211,422 | N/A |
| 6/30/2020 | 734,019 | 190,599 | 108,080 | 196,718 | N/A |
| 3/31/2020 | 711,320 | 174,062 | 116,245 | 178,610 | N/A |
| 12/31/2019 | 686,184 | 157,560 | 145,464 | 206,641 | N/A |
| 9/30/2019 | 662,198 | 139,543 | 83,362 | 160,274 | N/A |
| 6/30/2019 | 614,949 | 113,070 | 43,280 | 118,955 | N/A |
| 3/31/2019 | 586,648 | 99,631 | 23,827 | 101,309 | N/A |
| 12/31/2018 | 579,787 | 92,488 | 41,403 | 119,074 | N/A |
| 9/30/2018 | 572,994 | 85,857 | 91,950 | 125,700 | N/A |
| 6/30/2018 | 566,548 | 85,285 | N/A | 120,997 | N/A |
| 3/31/2018 | 556,159 | 82,101 | N/A | 127,695 | N/A |
| 12/31/2017 | 534,199 | 72,713 | N/A | 107,623 | N/A |
| 9/30/2017 | 517,908 | 67,704 | N/A | 63,732 | N/A |
| 6/30/2017 | 497,023 | 58,143 | N/A | 67,355 | N/A |
| 3/31/2017 | 497,354 | 57,592 | N/A | 49,230 | N/A |
| 12/31/2016 | 491,780 | 53,592 | N/A | 38,787 | N/A |
| 9/30/2016 | 492,584 | 56,562 | N/A | 40,808 | N/A |
| 6/30/2016 | 506,192 | 62,537 | N/A | 39,670 | N/A |
| 3/31/2016 | 501,649 | 61,043 | N/A | 49,913 | N/A |
| 12/31/2015 | 498,839 | 61,125 | N/A | 62,918 | N/A |
| 9/30/2015 | 495,455 | 58,897 | N/A | 75,502 | N/A |
| 6/30/2015 | 479,265 | 52,220 | N/A | 50,719 | N/A |
| 3/31/2015 | 454,147 | 46,786 | N/A | 54,919 | N/A |
| 12/31/2014 | 461,109 | 50,980 | N/A | 37,034 | N/A |
| 9/30/2014 | 450,545 | 52,461 | N/A | 38,017 | N/A |
| 6/30/2014 | 444,658 | 55,044 | N/A | 60,556 | N/A |
| 3/31/2014 | 457,281 | 60,774 | N/A | 54,886 | N/A |
| 12/31/2013 | 423,652 | 50,895 | N/A | 53,521 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4519's forecast earnings growth (6.2% per year) is above the savings rate (0.3%).
Earnings vs Market: 4519's earnings (6.2% per year) are forecast to grow slower than the JP market (7.9% per year).
High Growth Earnings: 4519's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4519's revenue (4.4% per year) is forecast to grow faster than the JP market (4.2% per year).
High Growth Revenue: 4519's revenue (4.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4519's Return on Equity is forecast to be low in 3 years time (17%).